On 15 March 2021, the Shenzhen Quality-Driven City Promotion Association released the "List of Enterprises Shortlisted for the 2nd Top 100 Shenzhen Brands". Shenzhen Beike Biotechnology Co., Ltd. stood out from all participating enterprises and was honored with the "Top 100 Shenzhen Brand Enterprises" title. The public announcement was successfully completed on 20 March. This is yet another honor for Beike Biotech, following its "Shenzhen Famous Brand" recognition in January!
The "Top 100 Shenzhen Brands" selection is guided by the Shenzhen Municipal Economy and Information Technology Commission, the Market and Quality Supervision Commission and the Futian District Government, hosted by the Shenzhen Quality-Driven City Promotion Association, and co-organized by the Shenzhen Institute of Standards and Technology, the Shenzhen Consumer Council and the Shenzhen Public Credit Center, attracting hundreds of outstanding enterprises in Shenzhen. After a rigorous review process, the Top 100 Shenzhen Brands Evaluation Working Committee assessed candidates across multiple dimensions – brand foundation capability, brand management capability, brand competitiveness and brand sustainable-development capability – through qualification screening, materials review, on-site inspection (random checks/third-party assessment), public review, comprehensive expert committee review and final approval by the evaluation working committee. From these processes, 100 enterprises were selected as the 2nd "Top 100 Shenzhen Brands".A brand is the core competitiveness of an enterprise and a precious intangible asset. Committed to becoming a leading enterprise driving the clinical translation of biotherapeutic technologies, Beike Biotech has, since its founding in Shenzhen in 2005, developed for 16 years in fields such as the clinical translation of biotechnology and stem cell basic research and clinical translation. Guided by the corporate values of "rigor, innovation, care and service", Beike Biotech adheres to the core value that "quality is the lifeblood of the enterprise", continuously enhancing the company's intrinsic strength through ongoing scientific innovation and quality management, and earning a strong reputation in the market.In recent years, through strategic transformation, Beike Biotech has continued to increase investment in research, technology and clinical translation and to expand brand-building, achieving a series of outstanding results. As of November 2020, the company has filed 108 patents in the cell technology field, of which 56 have been granted. The innovative "Comprehensive Cell Bank + Regional Cell Preparation Center + Cell Quality Inspection Platform" industrial development model provides an innovative public technology platform and infrastructure for the clinical translation of cell therapy technology, while also laying a data foundation for the future development of AI + biomedicine. In January 2020, Beike Biotech's research outcome "Key Technical Innovation and Clinical Application of Allogeneic Mesenchymal Stem Cells in Treating Refractory Lupus Erythematosus" received the 2019 National Technological Invention Award.These honors and achievements are the best testament to Beike Biotech's corporate strength, product quality and service capabilities, and the strongest assurance behind the broad recognition the company enjoys among customers in the market. The "Top 100 Shenzhen Brands" honor is both an affirmation of Beike Biotech's long-standing efforts and an encouragement and expectation for its future. Beike Biotech will continue to drive enterprise development through innovation, advance brand-building, and contribute to taking "Shenzhen brands" out of China and to the world.
